Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey-Reference-Cited by-同舟云学术

Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey

Published:2017-08-07 Issue:1 Volume:26 Page:251-260
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Brett Hauber A.,Mange Brennan,Price Mark A.,Wolin Daniel,Bensink Mark,Kaye James A.,Chandler David

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s00520-017-3841-2/fulltext.html

Reference15 articles.

1. Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw 6:109–118

2. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184

3. Neulasta® (pegfilgrastim) prescribing information (2016) Available from: http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.ashx . Accessed 9 December 2016

4. National Comprehensive Cancer Network (NCCN) (2015) Guidelines on myeloid growth factors, version 1. 2015. http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf . Accessed 1 September 2015

5. Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199–3212

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status;Cancer Treatment and Research Communications;2024

2. Pegfilgrastim OBI device use for neutropenia prevention: a scoping review;Acta Paulista de Enfermagem;2023-08-09

3. Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia;BMC Health Services Research;2023-05-23

4. Uso do dispositivo Pegfilgrastim OBI para prevenção de neutropenia: revisão de escopo;Acta Paulista de Enfermagem;2023

5. Effects of a Guideline-Informed Clinical Decision Support System Intervention to Improve Colony-Stimulating Factor Prescribing;JAMA Network Open;2022-10-24